A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2

Authors: Kang Wang^{1§}, Yunlong Cao^{3§}, Yunjiao Zhou^{2§}, Jiajing Wu^{4,§}, Zijing Jia^{1§}, Yaling Hu^{5§}, Ayijiang Yisimayi³, Wangjun Fu¹, Lei Wang¹, Pan Liu¹, Kaiyue Fan¹, Ruihong Chen^{1,6}, Lin Wang⁵, Jing Li⁵, Yao Wang³, Xiaoqin Ge⁵, Qianqian Zhang², Jianbo Wu², Nan Wang¹, Wei Wu², Yidan Gao², Jingyun Miao⁷, Yinan Jiang⁷, Lili Qin⁷, Ling Zhu¹, Weijin Huang⁵, Yanjun Zhang⁹, Huan Zhang⁸, Baisheng Li⁸, Qiang Gao⁵, Xiaoliang Sunney Xie^{3*}, Youchun Wang^{4*}, Qiao Wang^{2*} and Xiangxi Wang^{1,6*}

Affiliation:

¹ CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

² Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences; Shanghai Institute of Infectious Disease and Biosecurity; Shanghai Medical College, Fudan University, Shanghai 200032, China

³ Beijing Advanced Innovation Center for Genomics (ICG), Biomedical Pioneer Innovation Center (BIOPIC), School of life Science, Peking University, Beijing 100091, China

⁴ Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China

⁵ Sinovac Biotech Ltd, Beijing, China

⁶ Guangzhou Laboratory, Guangzhou, Guangdong, China, 510320

⁷ Acrobiosystems Inc, Beijing, China

⁸ Guangdong Provincial Center for Disease Control and Prevention

⁹ Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China

*Correspondence to: X.W. (Email: xiangxi@ibp.ac.cn) or Q.W. (Email: wangqiao@fudan.edu.cn) or Y.W. (Email: wangyc@nifdc.org.cn) or X.S.X. (Email: sunneyxie@biopic.pku.edu.cn)

§ These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 **Abstract: (~150 words)**

34 Emergence of variants of concern (VOC) with altered antigenic structures and waning
 35 humoral immunity to SARS-CoV-2 are harbingers of a long pandemic. Administration
 36 of a third dose of an inactivated virus vaccine can boost the immune response. Here,
 37 we have dissected the immunogenic profiles of antibodies from 3-dose vaccinees, 2-
 38 dose vaccinees and convalescents. Better neutralization breadth to VOCs, expeditious
 39 recall and long-lasting humoral response bolster 3-dose vaccinees in warding off
 40 COVID-19. Analysis of 171 complex structures of SARS-CoV-2 neutralizing
 41 antibodies identified structure-activity correlates, revealing ultrapotent, VOCs-
 42 resistant and broad-spectrum antigenic patches. Construction of immunogenic and
 43 mutational heat maps revealed a direct relationship between “hot” immunogenic sites
 44 and areas with high mutation frequencies. Ongoing antibody somatic mutation,
 45 memory B cell clonal turnover and antibody composition changes in B cell repertoire
 46 driven by prolonged and repeated antigen stimulation confer development of
 47 monoclonal antibodies with enhanced neutralizing potency and breadth. Our findings
 48 rationalize the use of 3-dose immunization regimens for inactivated vaccines.

49

50

51

52 **One sentence summary**

53 A third booster dose of inactivated vaccine produces a highly sifted humoral immune
 54 response *via* a sustained evolution of antibodies capable of effectively neutralizing
 55 SARS-CoV-2 variants of concern.

56

57

58

59

Main Text:

The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has lasted for one and a half years, resulting in an unprecedented public health crisis with over 4 million deaths globally. Progress in halting this pandemic seems slow due to the emergence of variants of concern (VOC), such as the B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma, also known as B.1.1.28.1) and more recent B.1.617.2 (Delta), that appear to be high transmissible and more resistant to neutralizing antibodies (1-4). While several types of COVID-19 vaccines are being deployed at a large scale, new variants are thought to be responsible for re-infections, either after natural infection or after vaccination, as observed in Brazil and the United States, respectively (5, 6). Closely correlated with these, a general decrease in immune protection against SARS-CoV-2 variants within 6-12 months after the primary infection or vaccination is also observed (6-8). The prospect of genetic recombination and antigenic drift in recent SARS-CoV-2 variants together with non-uniform immune protections arising from heterogeneously waning humoral immunity in COVID-19 convalescent or vaccinated individuals, point to the potential risks of a long-term pandemic that could endanger the global human health, diminishing social, economic and outdoor leisure activities. A plausible approach to solving this problem is the administration of a third dose of the vaccine somewhere between 6 and 12 months after the 2nd dose of vaccination for enhancing and prolonging the protection. However, not much is known about the immunogenic features of such a booster dose of a COVID-19 vaccine. In addition, there are large gaps in our understanding about correlating immunogenic findings from surrogate endpoints to gauge vaccine efficacy.

The CoronaVac, a 2-dose β -propiolactone-inactivated vaccine against COVID-19, has been approved for emergency use by the World Health Organization (9, 10). In human clinical trials (phase I/II, registration number: NCT04352608), a subgroup with a 3-dose immunization schedule at months 0, 1, 7 was also included. To evaluate immune features, we recruited 22 COVID-19 convalescents, 6 healthy participants (SARS-CoV-2 negative, confirmed by RT-PCR) and 38 volunteers who received

either 2 or 3 doses of the Coronavac vaccine for blood donation. The volunteers ranged from 16 to 69 years old (median 33); 30 (45.5%) were men and 36 (54.5%) were women. None of the volunteers recruited for vaccination was infected by SARS-CoV-2 prior to the study. Blood samples from convalescents and vaccinees collected 1.3 months after infection and the indicated times after vaccination were used in this study, respectively, to compare humoral immune responses elicited against circulating SARS-CoV-2 variants.

Neutralizing antibodies (NAbs) are a major correlate of protection for many viruses, including SARS-CoV-2, and have also provided the best correlate of vaccine efficacy. Several types of SARS-CoV-2 neutralization assays have been described using either live SARS-CoV-2 or a pseudo-typed reporter virus carrying SARS-CoV-2 spike protein (S). Both types of assays could yield reproducible neutralizing titers, with the pseudo-typed virus neutralization assay exhibiting higher sensitivity (11, 12). Neutralizing activity of plasma samples from 66 participants was measured against WT, B.1.351, P.1 and B.1.617.2 using live SARS-CoV-2 and VSV-pseudoviruses with the S from WT, B.1.1.7, P.1 variants and SARS-CoV (Fig. 1). The geometric mean half-maximal neutralizing titers (GMT NT₅₀) against live SARS-CoV-2 in plasma obtained from convalescents and from vaccinees (4 weeks after the final vaccination) suggest an approximately 60% higher neutralizing activity against WT after 3-dose inoculation when compared with 2-dose administration, and 20% higher than those from convalescents (Fig. 1A). Interestingly, for the samples from the convalescents, 2-dose and 3-dose vaccinees, neutralizing titers against B.1.351 were, on average, 7.7-fold, 5.7-fold and 3.0-fold reduced, respectively, compared with WT (Fig. 1A). Similarly, fold decreases in neutralization ID₅₀ titers against P.1 and B.1.617.2 for the three cohorts were 5.3, 4.3 and 3.1, and 5.3, 3.7 and 2.3, respectively (Fig. 1A). Overall, plasma of the 3-dose vaccinees displayed minimal reduction in neutralization titers against several authentic VOCs compared to the convalescents and 2-dose vaccinees (Fig. 1A). Remarkably, ~41% (9/22) and 50% (6/12) samples from the convalescents and 2-dose vaccinees, respectively, failed to reach 50% neutralization at a plasma dilution

of 1: 10, with ~14% (3/22) and 16% (2/12) showing a near ineffectiveness in neutralizing B.1.351 *in vitro* (Fig. 1A). By contrast, only 1 out of 14 samples from the 3-dose vaccinees exhibited a weak neutralizing titer below 10 (Fig. 1A). Importantly, the 3-dose vaccinees showed over 2.5-fold higher neutralizing potency against B.1.617.2 than the convalescents and 2-dose vaccinees (Fig. 1A). The GMT NT₅₀ values measured by a VSV-pseudovirus with the WT S were 840, 660 and 1,176 for convalescents, 2-dose and 3-dose vaccinees, respectively, which were 8-10-fold greater than those determined by live WT SARS-CoV-2 (Fig. 1A, 1B), confirming higher sensitivity of pseudovirus-based assays in determining neutralizing titers. In line with the results of live SARS-CoV-2 neutralization assay, the mean fold decrease in the neutralization of B.1.1.7 relative to the WT was 2.8-fold for convalescents, 2.2-fold for 2-dose vaccinees and 1.7-fold for 3-dose vaccinees (Fig. 1B). Similarly, plasma from convalescents, 2-dose and 3-dose vaccinees exhibited a 4.5-fold, 2.9-fold and 2.4-fold reduction, in NAb titers against P.1, respectively, when compared to the WT (Fig. 1B). These results reveal that a third-dose boost of inactivated vaccine leads to enhanced neutralizing breadth to SARS-CoV-2 variants, bolstering the potential to ward off VOCs effectively when compared to convalescent plasma. Of note, neither vaccination nor SARS-CoV-2 infection boosts distinct neutralizing potency against SARS-CoV, presumably due to the relatively far phylogenetic relationship (Fig. 1B).

To seek information on potential binding-neutralization correlates, the abilities of antibodies present in plasma to bind the receptor-binding domain (RBD), N-terminal domain (NTD), S-trimer and nucleoprotein (N) from SARS-CoV-2 and its variants were measured by enzyme-linked immunosorbent assay (ELISA). As expected, all COVID-19 convalescents and vaccinees exhibited high anti-RBD, anti-NTD, anti-S and anti-N titers for SARS-CoV-2 variants, but weak antibody reactivity to SARS-CoV (Fig. 1C and fig. S1). Unexpectedly, the amount of N-specific IgG elicited by 2-dose and 3-dose vaccination schedules was 2-6-fold lower than those of convalescents, and 2-6-fold lower than the antibodies targeting S or RBD in vaccinees, reflecting distinct serological profiles (Fig. 1C and fig. S1). Overall

plasma neutralizing activity against the WT was substantially correlated with anti-S and anti-RBD binding titers in ELISA. However, only marginal correlates between binding and neutralization potency were established for VOCs (fig. S2). In spite of this, a 3-dose administration elicits a broader range of antibody binding activities to VOCs with minimal decreasing folds than those of 2-dose vaccination and convalescents (Fig. 1D and fig. S2).

To evaluate the nature of humoral immune response elicited by a booster dose of CoronaVac, the S-specific IgA, IgM and IgG titers and neutralizing activities against SARS-CoV-2 variants were monitored before and 4 weeks after the third immunization. S-specific IgM and IgA titers were generally lower and were not significantly boosted in response to the third-dose vaccination (Fig. 1E). Similar to most convalescents (2), approximately 80~90% of both anti-S IgG and NAb titers against the WT waned 6 months after the second vaccination (13), while the third-dose administration of CoronaVac boosted these titers by ~20-fold at 4 weeks post vaccination (Fig. 1E and F). Significantly, vaccinees 6 months after the second immunization did not have detectable *in vitro* neutralizing activities against B.1.351, P.1 and B.1.617.2, while all vaccinees exhibited a robust recall humoral response to efficiently neutralize circulating variants post the third-dose vaccination (Fig. 1E and F). To further characterize the expeditiousness, longevity and immunological kinetics of recall response stimulated by the third-dose immunization, neutralizing potencies at days 0, 7, 14, 28, 90 and 180 post the third-dose vaccination were determined (Fig. 1G and H). Remarkably, NAb titer surged by ~8-fold (from 7 to 53) at week 1, peaked by ~25-fold increase (up to 177) at week 2 after the 3rd-booster and slowly decreased over time (Fig. 1G). Notably, NAb titer was maintained at around 60 on 180 days post the 3rd-booster, comparable to the high level of NAb titer elicited by the 2-dose administration (Fig. 1H). Taken together, these serological results reveal a third-dose booster can elicit an expeditious, robust and long-lasting recall humoral response.

The molecular mechanism underlying these potent, broad and durative antibody

184 responses elicited by a third-dose booster 6 months after the administration of the
185 second dose of the vaccine, might involve ongoing antibody somatic mutation and
186 evolution of antibody by affinity maturation through prolonged and repeated antigen
187 stimulation (14, 15). Although circulating antibodies derived from plasma cells wane
188 over time, long-lived immune memory can persist in expanded clones of memory B
189 cells (16). Thereby, we used flow cytometry to sort the SARS-CoV-2 S-trimer-
190 specific memory B cells from the blood of seven selected CoronaVac vaccinees,
191 including four samples from 3-dose vaccinees and three samples from 2-dose
192 vaccinees (Fig. 2A and fig. S3). The averaged percentage of S-binding memory B
193 cells in 3-dose vaccinees was substantially greater than those in 2-dose vaccinees
194 (Fig. 2A and fig. S3). Due to differences in labeling strategies employed for sorting
195 SARS-CoV-2-specific B cells, the above percentage of memory B cells was not
196 directly comparable with those reported in naturally infected individuals and in
197 mRNA vaccinated individuals. The gated double-positive cells were single cell
198 sorted and immunoglobulin heavy (*IGH*; IgG isotype) and light (*IGL* or *IGK*) chain
199 genes were amplified by nested PCR. Overall, we obtained 422 and 132 paired heavy
200 and light chain variable regions from S-binding IgG⁺ memory B cells from four 3-
201 dose and three 2-dose vaccinees, respectively (Fig. 2B and fig. S4). Surprisingly,
202 expanded clones of cells comprised 45-61% of the overall S-binding memory B
203 compartment in 3-dose vaccinees, which is approximately 2-fold higher than those
204 in COVID-19 convalescents and in mRNA or 2-dose vaccinated individuals (Fig. 2B
205 and C). When compared to 2-dose vaccinees, the increase in the number of persistent
206 clones and various clonal compositions in 3-dose vaccinated group suggested an
207 ongoing clonal evolution (Fig. 2B and C). Shared antibodies with the same
208 combination of *IGHV* and *IGLV* genes in 3-dose vaccinees comprised ~20% of all
209 the clonal sequences. Similar to natural infection and mRNA vaccination (2, 14, 16),
210 *IGHV3-30*, *IGHV3-53* and *IGHV1-69* remained significantly over-represented in 3-
211 dose vaccinees (fig. S5). Meanwhile, notable differences in the frequency of human
212 V genes between 3-dose vaccinated and the other two groups were observed as well
213 (fig. S5). In 3-dose vaccinees, *IGHV3-21*, *IGHV4-39* and *IGHV7-4-1* were largely
214 abundant, but *IGHV5-51*, *IGHV3-66* and *IGHV1-2* were significantly scarce when

compared to the other two groups (fig. S5), indicative of memory B cell clonal turnover. Notably, large-scale, single-cell sequencing datasets generated from two cohorts of 2-dose, 3-dose vaccinees and a group of convalescents revealed no distinct preference in the frequency of *V* genes at total B cell repertoire level (fig. S6), suggesting that a large abundance of antibodies with low expression or affinities exist in B cells. Additionally, the number of nucleotide mutations in the *V* gene in 3-dose vaccinees is higher than those in both 2-dose vaccinees and naturally infected individuals assayed after 1.3 and 6.2 months, but slightly lower than those in convalescent individuals 1 year after infection (Fig. 2D), revealing ongoing somatic hypermutation of antibody genes. There was no significant difference in the length of the IgG CDR3 between vaccinated (either mRNA or inactivated) and convalescent (after 1.3 or 6.2 or months) groups (fig. S7). These results reveal that a third-dose booster 6 months after the second vaccination elicits an enhanced and anamnestic immune response, which is led by clonal evolution of memory B cell and ongoing antibody somatic mutations, resulting in enhanced neutralizing potency, breadth and longevity of the immune response against SARS-CoV-2.

To further explore the immunogenic characteristics of the antibodies obtained from memory B cells in 3-dose vaccinees, 48 clonal antibodies, designated as XGv01 to XGv50 (no expression for XGv37 and XGv48) were expressed and their antigen binding abilities verified by ELISA (fig. S8). Biolayer interferometry affinities (BLI) measurements demonstrated that all antibodies bound to WT SARS-CoV-2 at sub-nM levels (fig. S9 and table S1). The normalized geometric mean ELISA half-maximal concentration (EC_{50}) revealed that all antibodies ($EC_{50}=4.5$ ng/ml) obtained from 3-dose vaccinees, in particular RBD-specific mAbs ($EC_{50}=3.5$ ng/ml), possessed higher binding activities than RBD-mAbs from early convalescents (at 1.3 and 6.2 months after infection, $EC_{50}=5.0$ and 6.8 ng/ml, respectively) and mRNA ($EC_{50}=4.4$ ng/ml) vaccinated individuals (2, 14-18), but were comparable to those from late convalescent individuals ($EC_{50}=2.6$ ng/ml) assessed at 12 months after infection (Fig. 2E). These results indicate the possibility of the loss of antibodies with low binding affinities over time or an ongoing increase in affinity under the

repeated exposures of antigen. Among these antibodies tested, 26 bound to RBD, 16 targeted NTD, and 6 interacted with neither RBD nor NTD, but bound S1 (S1/non-RBD-NTD) (fig. S9 and table S1). Pseudovirus neutralization assay revealed that all RBD-specific antibodies, 10 (~60%) of the 16 NTD-directed antibodies and 3 (~50%) of the 6 S1/non-RBD-NTD antibodies were neutralizing, presenting a relatively high ratio for NABs (Fig. 2F, fig. S10 and table S2). Authentic SARS-CoV-2 neutralization assay results largely verified their neutralizing activities, albeit with that higher concentrations were required for some NABs (fig. S11). Compared to RBD antibodies, many NTD NABs exhibited very limited neutralizing activities. Notably, approximately 30% of RBD antibodies showed extra potent activities with half-maximal inhibitory concentration values (IC_{50}) < 0.1 nM. In line with binding affinity, the normalized geometric mean IC_{50} of the RBD antibodies of 3-dose vaccinees was 80 ng/ml, substantially lower than those from naturally infected individuals (ranging from 1.3 to 6.2 months, IC_{50} =130-160 ng/ml) and mRNA vaccinated individuals (IC_{50} =150 ng/ml), but similar to those from late convalescents (IC_{50} =78 ng/ml) (Fig. 2E) (2, 14-18). The overall increased neutralizing potency might have resulted from the ongoing accumulation of clones expressing antibodies with tight binding and potent neutralizing activities. Our experimental observations are consistent with a more recent study where antibodies generated from clonal B cells after 12 months showed enhanced neutralizing activities (14, 15).

To examine the cross-reactivity against VOCs and other human coronaviruses, binding responses of these antibodies to WT, B.1.1.7, P.1, B.1.351, B.1.617.2, SARS-CoV, HuCoV NL63, HuCoV 229E and HuCoV HKU1 were measured. All but 2 of the 48 antibodies showed strong cross-binding to SARS-CoV-2 VOCs and about one-third of antibodies exhibited clear cross-reactivity to SARS-CoV, but none of these bound to HuCoV NL63, HuCoV 229E or HuCoV HKU1 (fig. S12). For ~20% and 25% of RBD- and NTD-targeting antibodies, respectively, binding affinities against B.1.351/B.1.617.2 were over 10-fold reduced compared with WT (Fig. 2E). To further determine the neutralization breadth, the neutralizing activity of these antibodies was assayed against five VOCs and SARS-CoV. Out of 26 RBD NABs,

24 possessed cross-neutralization activity against all five SARS-CoV-2 VOCs (Fig. 2F and fig. S13). Among these, six RBD antibodies could cross-neutralize SARS-CoV, of which 2 exhibited more potent neutralization activity against SARS-CoV with IC₅₀ values of 41 and 73 ng/ml. However, most of the NTD and S1/non-RBD-NTD NAbs lost their abilities to inhibit viral infection (Fig. 2F and fig. S13), indicative of higher variations for the NTD in VOCs. In comparison with NAbs from early convalescents, antibodies isolated from 3-dose vaccinees showed overall enhanced neutralizing potency and breadth to VOCs.

RBD is one of the main targets of neutralization in SARS-CoV-2 and other coronaviruses. Due to its inherent conformational flexibility, RBD exists in either an “open” (ACE2 receptor accessible) or “closed” (ACE2 receptor inaccessible) configuration (19, 20), bearing antigenic sites with distinct “neutralizing sensitivity”. To dissect the nature of the epitopes of RBD targeted by NAbs, 171 SARS-CoV-2 RBD-targeting NAbs with available structures (2, 15, 21-82), including 8 cryo-EM structures determined in this manuscript (fig. S14-S15 and table S3), were examined. By using cluster analysis on epitope structures, the antibodies were primarily classified into six sites (I, II, III, IV, V and VI) (Fig. 3A and fig. S16), that are related to the four or five classes assigned in recent studies (22, 31). Additionally, we superimposed structures of RBDs from these complex structures and calculated the clash areas between any 2 NAbs (Fig. 3B). Both strategies yielded identical results. Combining the results of the characterization of binding and neutralization studies reported previously with those determined here, the key structure-activity correlates for the six classes of antibodies were analyzed (Fig. 3). Antibodies with sites I, II and III, most frequently elicited by SARS-CoV-2 early infection, target the receptor-binding motif (RBM), and potentially neutralize the virus by blocking the interactions between SARS-CoV-2 and ACE2 (Fig. 3C and D). Class I antibodies, mostly derived from *IGHV3-53/IGHV3-66* with short HCDR3s (generally <15 residues), recognize only the “open” RBD, and make contact with K417 and N501, but not L452/T478/E484 (Fig. 3C and D, and fig. S16-S17). Notably, mutations such as K417N, L452R, T478K, E484K and N501Y, or combinations of these mutations,

identified in several VOCs like B.1.1.7, B.1.617.2, P.1 and B.1.351, have been demonstrated to be key determinants for the viral escape of neutralization by many NABs (fig. S18) (1, 81). Approximately ~75% and 60% of class I NABs were significantly impaired in binding and neutralizing activities against B.1.351 as well as P.1, respectively, due to the combined mutations of K417N/T and N501Y (Fig. 3D and E, and fig. S18). Contrarily, Class III antibodies that are encoded by *IGHV1-2* and other variable heavy (VH)-genes and bound to RBD either in “open” or “closed” conformation, extensively associate with E484, and partially with L452, but not K417/T478/N501 (Fig. 3D and fig. S17C). Interestingly, *IGHV3-53/IGHV3-66* RBD antibodies with long HCDR3s (>15 residues) switch their epitopes from the site I to site III, indicating a clear antigenic drift during the process of somatic hypermutations (fig. S17C). Disastrously, over 90% class III antibodies showed a complete loss of activity against B.1.351 as well as P.1 largely owing to an E484K mutation (Fig. 3E). Against B.1.617.2, the substantially decreased activity of ~half of the class III antibodies is presumably mediated by L452R (Fig. 3E). Class II antibodies use more diverse VH-genes and target the patch lying between sites I and III (Fig. 3D and fig. S19). Surprisingly, antibodies binding to site II possess relatively lower specificity in recognition of epitope clusters ranging from K417, L452, S477, E484 to N501 (fig. S16). Like site I, site II can only be accessed when the RBD is in “open” conformation (Fig. 3A). As expected, the effects of mutations on the activity of class II antibodies were severe, two-thirds of these antibodies had >10-fold fall in neutralization activities against VOCs (Fig. 3E). Overall, the above analysis reveals that the RBD mutations identified in several VOCs can significantly reduce and, in some cases, even abolish the binding and neutralization of classes I to III antibodies, albeit being the most potent neutralizing antibodies against WT SARS-CoV-2.

By contrast, antibodies of the other three classes recognize evolutionarily conserved regions distinct from the RBM and some of these are often cross-reactive with other sarbecoviruses (65-67, 79). The binding of class IV antibodies, albeit attached to the apical shoulder of the RBM, is focused on a condensed patch that comprises residues 345-346, 440-441, 444-446, 448-450, which are not related to mutations observed in

VOCs (Fig. 3C and fig. S16). Related to the binding position, site IV epitopes, accessible in both “open” and “closed” conformations, exist either as partially overlapped with or outside ACE2 binding sites (Fig. 3A). Interestingly, class IV antibodies can execute their neutralizations via multiple mechanisms, such as (i) direct blockage of RBD-ACE2 associations, (ii) bridging adjacent “closed” RBDs to lock the S-trimer into a completely closed prefusion conformation, (iii) blockage of viral membrane fusion by locking conformational changes of the S-trimer, or (iv) Fc-dependent effector mechanisms (31, 62, 67). Class IV antibodies, e.g. 1-57, 2-7, S309 and BD-812, hold the greatest potential for harboring ultra-potent neutralization activity and markedly high tolerance to most VOCs (63, 67). Not surprisingly, all class IV antibodies, but CV07-270, exhibited excellent neutralizing breadth and potency to VOCs (Fig. 3E). The probable reason underlying the exception could be that CV07-270 bears an unusually long HCDR3, directly contacting E484, distal to the site IV (46). Site V locates beneath the RBM ridge, opposite to the site I, and adjacent to the site III. None of the class V antibodies compete with ACE2 binding (Fig. 3D and fig. S17). Due to ~40% targeting frequency to L452, B.1.617.2, but not other VOCs, partially decreased the activities of some class V antibodies (Fig. 3E). Class VI antibodies recognize a patch on one side of the RBD, distal from the RBM. Among these, some compete with ACE2 binding, while some do not, and this largely depends on the orientation/pose of the antibodies bound. Both sites V and VI contain cryptic epitopes that are only accessible when at least one RBD is in the open state (Fig. 3A and C). In some cases, e.g. FC08 and CR3022, belonging to class V and VI, respectively, epitopes are only accessible in the prefusion S-trimer under the condition that all RBDs are open, suggesting that binding of these antibodies would facilitate the destruction of the prefusion S-trimer (83, 84). In spite of less potency, antibodies targeting sites V to VI are mostly tolerant to the VOCs.

Low levels of NABs elicited by either natural infection or vaccination during *in vivo* viral propagation may impose strong selection pressure for viral escape, leading to an increase in the number of SARS-CoV-2 variants. To further understand the drivers of viral evolution, we constructed immunogenic and mutational heatmaps for RBD

using the 171 NAb complex structures to estimate *in vivo* NAb-targeting frequencies on the RBD and viral mutation frequencies (calculated from the datasets in the GISAID), respectively (Fig. 3D and fig. S19). Briefly, for each antibody, we identified epitope residues and calculated the frequency of each RBD residue being recognized by antibody. Immunogenic heatmap revealed that the epitope residues of sites I to III showed predominantly higher NAb recognition frequencies (about 53.8, 55.0 and 49.2 antibodies per residue on average for site I, II and III, respectively) compared with those of sites IV to VI (about 19.4, 9.1 and 14.3 antibodies per residues on average for site IV, V and VI, respectively), suggesting that class I to III antibody epitopes are “hot” immunogenic sites (Fig. 3D and fig. S19). In line with this, residues within sites I to III exhibited dramatically higher mutation frequencies, as revealed in circulating variants that include mutations of K417, L452, S477, T478, E484 and N501 residues (Fig. 3D and fig. S19). Surprisingly, none of the top 9 hottest immunogenic residues had a high mutation frequency. In particular, residues, such as F486, Y489, Q493, L455, F456, *et.al* (top 5, having 96, 96, 81, 73 and 70 antibodies per residue, respectively) with large side chains exhibited extremely low mutation frequencies in circulating SARS-CoV-2 strains (Fig. 3D and fig. S20). It’s worthy to note that all these residues are extensively involved in the recognition of ACE2. The buried surface area (BSA) of these residues upon binding to ACE2 confirmed that extensive interactions would be significantly reduced by amino acid substitutions, thereby affecting ACE2-mediated viral entry. Thus, genetic, structural and immunogenic analysis explains why mutations at these positions would not be selected.

A few studies have reported that a subset of NTD-targeting antibodies can be as potent as best-in-class RBD specific antibodies. They work *via* inhibiting a step post-attachment to cells like blocking fusion of the virus to the host cell membrane (85-88). We performed cluster analysis on 26 structures of the NTD-NAb complexes (including 2 structures solved in this manuscript) (fig. S21A) (54, 85-93). A dominant site α , defined as the “supersite” in more recent studies (85-88), comprising of three flexible loops (N1, N3 and N5), is the largest glycan-free surface of NTD

facing away from the viral membrane (facing up). Antibodies targeting site α generally exhibited the most potent neutralizing activity compared to other sites on the NTD (85, 90) (fig. S21B and C). The NTD supersite antibodies are primarily derived from a subset of VH-genes with an over-representation of *IGHV1-24*. Sites β and γ , as the left and right flank clusters, construct a shallow groove beneath the supersite and locate at the back of the groove, eliciting less potent antibodies. By contrast, δ antibodies, bound to a patch beneath the groove have their Fab constant domains directed downward toward the virus membrane (facing down) (fig. S21B and C). In line with binding orientation, many of the δ antibodies were shown to present infection enhancing activities *in vitro* (54, 90). Perhaps correlated with being a “hot” immunogenic site that is amenable to potent neutralization, highly frequent mutations, including a number of deletions within the NTD supersite were identified in most VOCs under ongoing selective pressure, leading to significant reduction and in some cases even complete loss of neutralization activity for these NTD supersite NABs (94).

More recent studies have reported that SARS-CoV-2 infection can produce a long-lasting memory compartment that continues to evolve over 12 months after infection with ongoing accumulation of somatic mutations, emergence of new clones and increasing affinity of antibodies to antigens (14, 15). Consequently, an increase in breadth and overall potency of antibodies produced by memory B cells over time has been revealed (14), akin to the experimental observations elicited by a 3-dose vaccination strategy using an inactivated vaccine described in this study. To investigate whether changes in the frequency of distribution of the six types of RBD antibodies is associated with evolution time, we collated and categorized human SARS-CoV-2 NABs from available literatures. For antibody clustering, we combined structural and square competition matrix analysis for 273 RBD NABs in total (Fig. 4A and fig. S22). In the earliest documented studies (before Dec 2020), NABs belonging to classes I to III were predominantly identified in early COVID-19 convalescent and 2-dose vaccinated individuals (defined as early time point), accounting for up to ~80% of total antibodies. By contrast, a low ratio of NABs from

IV to VI was reported possibly due to their less potent activities at the early time point (Fig. 4A). In recent literatures (after Dec 2020), NAbS with enhanced neutralizing potency and breadth from IV to VI have substantially been enriched in the late convalescents or 3-dose vaccinees, almost equal in frequency to antibodies from I to III and further becoming ascendant in individuals immunized with 3 doses of inactivated vaccine (Fig. 4A). Differential frequency of distribution of antibody types may provide an additional possible explanation for the observed enhanced neutralizing breadth of plasma in late convalescent individuals and 3-dose vaccinees. These results suggest that memory B cells display clonal turnover after about 6 months, subsequently resulting in changes in the composition of antibodies in B cell repertoire and thereby partially contributing to enhanced activities of antibodies secreted in the plasma over time. To explore the underlying mechanism, we measured the binding affinities of 167 type-classified antibodies that are also further categorized into early and late time point groups (table S1 and fig. S9). For the late time group, there was a 10-20 fold increase in binding affinity for individual classes, compared to those in the early time point group (Fig. 4B). In early time point group, antibodies from IV to VI exhibited higher binding affinities to the RBD than those from I to III, in particular, antibodies from V and VI despite limited numbers (Fig. 4B). Possibly higher affinities for these antibodies are required to accomplish neutralization successfully. Thus, most antibodies from V and VI with low affinities and activities might be screened out in the early time point. In the late point group, sub-*nM* binding affinities for individual class antibodies with no distinct variations were observed, reflecting ongoing affinity maturation over time. This might also explain the observation that some antibodies, from I to III isolated in the late time point possess potent cross-neutralization activities (Fig. 3E). Our antibody clustering and *V* gene usage analysis suggests that individual class antibodies can be derived from multiple *V* genes and the shared *V* gene antibodies belong to different classes. To decipher the intrinsic trends in the relationship between binding affinity and somatic hypermutation (SHM) rate, we determined the relative affinity (K_D) and calculated the SHM rate of antibodies that are encoded by the same *V* gene and belong to the same class. The measured K_D -SHM plots and K_D -SHM log-log plots of

class I antibodies (n=61), including 32 NABs derived from *IGHV3-53*, show least squares fitting of data to a power law with a strong correlation of -0.81 for *IGHV3-53* antibodies (-0.55 for all class I antibodies) (Fig. 4C). The absolute value of its slope corresponding to a free energy change per logarithm (base e) *SHM* of cal nmol^{-1} , where free energy change is $4.98RT + 1.48RT \ln(SHM)$ ($R = 2.0 \text{ cal K}^{-1} \text{ nmol}^{-1}$ and $T = 298 \text{ K}$). Antibodies with adequate numbers tested from II and III exhibited similar trends by following a power law, among which *IGHV3-66* antibodies in class II yielded a compelling correlation of -0.94 despite 6 plots involved in the fitting (Fig. 4C). These trends indicate that as the SHM increase, the binding energy increases and K_D value decreases.

More recently, the B.1.617.2 variant has contributed to another surge in COVID-19 cases worldwide, accounting for ~90% of new cases in the UK and >40% in the US, despite the fact that increasing number of people have been vaccinated. Evaluation of the effectiveness of several vaccines performed recently suggests that the efficacy for VOCs correlates with full vaccination status and the time that has passed since vaccination (95, 96). These may indicate that the effectiveness of the vaccines has started to decline as months pass after vaccination due to fading immunity. Our results demonstrate that a third-dose booster of inactivated vaccine can elicit an expeditious, robust and long-lasting recall humoral response which continues to evolve with ongoing accumulation of somatic mutations, emergence of new clones and increasing affinities of antibodies to antigens, conferring enhanced neutralizing potency and breadth. Collectively, our findings rationalize the use of 3-dose vaccination regimens.

Acknowledgments: We thank Dr. Xiaojun Huang, Dr. Boling Zhu, Dr. Lihong Chen, Dr. Xujing Li and Dr. Gang Ji for cryo-EM data collection, the Center for Biological Imaging (CBI) in Institute of Biophysics for EM work and thank Dr. Yuanyuan Chen, Zhenwei Yang for technical help with BLI experiments. We also thank Prof. David Ho and Prof. Barton Ford Haynes for generous gift of the sequences of two reference mAbs. Work was supported by the Strategic Priority Research Program

(XDB29010000, XDB37030000), CAS (YSBR-010), National Key Research and Development Program (2020YFA0707500, 2018YFA0900801), Emergency Key Program of Guangzhou Laboratory, Grant No. EKPG21-09 and Beijing Municipal Science and Technology Project (Z201100005420017). Xiangxi Wang was supported by Ten Thousand Talent Program and the NSFS Innovative Research Group (No. 81921005). **Author contributions:** X.W., Q.W., Y.W., X.S.X and Y.C. conceived, designed and coordinated the experiments. Y.Z., A.Y., Y.W., Q.Z. and J-B.W. cloned and produced antibodies. K.W., Z.J., K.F., J.M., Y.J. and L.Q. expressed and purified all recombinant antigen proteins used in this manuscript. J-J.W., Y.H., L.W., J.L., X.G., Y-J.Z., H.Z. and B-S.L performed pseudovirus and authentic virus neutralization experiments. K.W., L.W., P. L., WJ.F, N.W and L.Z performed structural study. Y.C., Y.Z., W.W. and Y.G. prepared PBMCs and flow cytometry sorting. Y.C. and A.Y. performed 10X sequencing library construction. Z.J. and K.F performed BLI assay. Y.H. and Q.G recruited volunteers and coordinated the collection of blood samples. All authors analyzed data; X.W wrote the manuscript with input from all authors. **Competing interests:** All authors have no competing interests. **Data and materials availability:** Cryo-EM density maps of the SARS-CoV-2 S trimer in complex with XGv013 or XGv043, the SARS-CoV-2 S trimer in complex with XGv004, XGv030 and XGv016; the SARS-CoV-2 S trimer in complex with XGv026 and XGv046, and the SARS-CoV-2 S trimer in complex with XGv018, XGv038 and XGv42 have been deposited at the Electron Microscopy Data Bank with accession codes EMD-UUUU, EMD-WWWW, EMD-XXXX, EMD-YYYY and EMD-ZZZZ, respectively.

Figure legends

Fig. 1 A 3rd-dose booster of an inactivated vaccine elicits an expeditious and long-lasting recall antibody response

Plasma neutralizing activity evaluated by authentic SARS-CoV-2 (A) and pseudo-typed SARS-CoV-2 neutralization assays (B) Left: half-maximal neutralizing titer (NT₅₀) values for plasma from COVID-19 convalescents, 2-dose, 3-dose CoronaVac vaccine recipients (at week 4 after the last dose of vaccination) and negative controls (pre-COVID-19 historical control) against live SARS-CoV-2 WT, B.1.351, P.1 and B.1.617.2, and VSV-based SARS-CoV-2 pseudoviruses bearing WT or B.1.1.7 or P.1 S protein. Black bars and indicated values represent geometric mean NT₅₀ values. Statistical significance was determined using the two-tailed Wilcoxon matched-pairs test. Experiments were repeated in triplicate. Dotted lines indicate the limit of detection. Right: fold decrease in neutralization for each variant relative to WT for

each cohort of plasma samples (calculated from the left datasets) is shown.

(C) IgG endpoint antibody responses specific to the N, RBD and S of WT SARS-CoV-2 were measured in plasma samples collected from cohorts as described earlier.

(D) Fold decrease in specific binding to the RBD, NTD and S for each variant over WT for each cohort of plasma samples as described above.

(E) IgA, IgM and IgG endpoint antibody titers specific to the S of WT SARS-CoV-2 or its variants in plasma samples collected from vaccinees before and 4 weeks after the 3rd-dose immunization.

(F) Neutralizing titers against live SARS-CoV-2 WT, P.1, B.1.351 and B.1.617.2 for plasma from vaccinees before and 4 weeks after the 3rd-dose immunization. Black bars and indicated values represent geometric mean NT₅₀ values.

(G) Longitudinal neutralizing titers of plasma from 3-dose vaccinees at days 0, 7, 14, 28, 90 and 180 post the 3rd-dose vaccination. The geometric mean NT₅₀ values are labeled.

(H) Kinetics of the 3rd-dose booster elicited recall response as indicated during monitoring of NAb titers at different time points. The green and blue curves show the changes in kinetics of NAb titers for pre-3rd-dose and post-3rd-dose vaccination, respectively.

Fig. 2 Memory B cell antibodies elicited by a 3rd-dose booster of an inactivated vaccine

(A) Representative flow cytometry plots showing dual allophycocyanin (APC)-S- and phycoerythrin (PE)-S-binding B cells for vaccinees and control donor.

(B) Pie charts represent the distribution of antibody sequences from the four 3-dose vaccinees. The number in the inner circle is the number of sequences analyzed here. Pie-slice size is proportional to the number of clonally related sequences. The black outline indicates the frequency of clonally expanded sequences detected individually. Colored slices reveal clones that share the same *IGHV* and *IGLV* genes.

(C) Graph shows relative clonality among seven individuals who received 2-dose or 3-dose of inactivated vaccines. Relative clonality for COVID-19 convalescents assayed at 1.3, 6.2 and 12 months after infection, as well as 2-dose mRNA vaccine recipients (2, 14, 18), previously described by Michel's group, was compared. Black

horizontal bars indicate mean values. Statistical significance was determined using two-tailed t-test.

(D) Number of somatic nucleotide mutations in the *IGHV* (left) and *IGLV* (right) in antibodies from vaccinees, including 2-dose or 3-dose of inactivated vaccines and 2-dose of mRNA vaccines and COVID-19 convalescents assayed at 1.3, 6.2 and 12 months after infection (2, 14, 18).

(E) Normalized ELISA binding (EC_{50}) by antibodies isolated from the 3-dose inactivated and 2-dose mRNA vaccinees (ref) as well as COVID-19 convalescents to SARS-CoV-2 S trimer (left) and normalized pseudovirus neutralization activity (IC_{50}) (right) against SARS-CoV-2 assayed at 1.3, 6.2 and 12 months after infection (ref). Among these, eight antibodies reported by Michel's group were expressed and assessed for both binding by ELISA and pseudovirus neutralization activity for normalized comparison here. Black horizontal bars indicate mean values.

(F) BLI binding affinities (upper panel) and pseudo-typed virus neutralization (bottom panel) by antibodies isolated from the 3-dose vaccinees to circulating SARS-CoV-2 variants. Color gradient for upper panel indicates K_D values ranging from 0 (green), through 2.5 (yellow) and 5 (red) to 25 nM (purple). Gray suggests no/very limited binding activity (>1000 nM). Color gradient for bottom panel indicates IC_{50} values ranging from 0 (green), through 20 (yellow) and 200 (red) to 2000 ng/ml (purple). Gray suggests no/very limited neutralizing activity (>2000 ng/ml).

Fig. 3 Structural landscape and immunogenic features of RBD NAb

(A) Structure-based antigenic clustering of SARS-CoV-2 RBD NAb. A total of 171 RBD NAb with available structures were classified into six clusters (I, II, III, IV, V and VI). NAb that can block ACE2 binding or not are outlined by light pink and light yellow, respectively. NAb that can attach to the closed RBD or not are outlined by gray blue and gray green, respectively.

(B) Superimposition matrix of 171 RBD NAb structures' output from clashed areas (Å²) between variable regions of any two Fab fragments showing the clustering into

six antibody classes.

(C) Surface representative model of six types of NAbs bound to the RBD. Fab fragments of six representative antibodies are shown in different colors and the RBD is colored in gray. Insets illustrate the antigenic patches targeted by six representative antibodies. Dashed dots indicate the overlaps between two adjacent antigenic patches.

(D) Structural landscapes of the six classes of RBD NAbs (upper panel). Antigenic patches (with targeting frequency >30%) recognized by six classes of NAbs are outlined in the assigned color scheme (same to Fig. 3C), among which residues with “hot targeting frequency” (generally over 65%, but over 85% in class I) are shown in bright colors corresponding to the patches they belong to. Residues involved in two (such as Y489, L452) or three (such as F486) neighboring antigenic patches are presented in a mixed color. Representative “hot” antigenic residues are labeled. Middle: hot map for antigenic residues on the RBD. Per residue frequency recognized by the 171 NAbs were calculated and shown. The top 9 of the hottest antigenic residues and key residues with substitutions in several VOCs are marked and labeled. Bottom: hot map for circulating variants with mutations on the RBD. Mutation frequency for each residue was calculated based on the datasets from GISAID.

(E) Immunogenic characteristics of six classes of RBD-targeting NAbs. Hot maps show relative fold changes in K_D values (up) and IC_{50} values (down) against several VOCs for the six classes of NAbs, including previously reported (97-108) and newly isolated antibodies described in this manuscript. Color gradients for upper and bottom panels indicate relative fold changes and are shown at right side. “-”: no related datasets in the original studies and related references are listed. Ref “A” indicates that the datasets were produced in this manuscript. Other letters in Ref correspond to different reference numbers shown as below. B – 91 and this manuscript, C – 99 and this manuscript, D – 97, E – 30, 81, 103 and 104, F – 99, G – 98, H – 100 and 108, J – 101, K – 94 and 102, L – 105 and 106, M – 94, N – 105, O – 107, P – 82, Q – 66, respectively.

Fig. 4 Antibody evolution and affinity maturation

(A) Uniform manifold approximation and projection (UMAP) plot displaying the antibodies defined as the early time point group (left) and late time point group (right). The antibodies are colored based on their cluster assignments by the hierarchical clustering algorithm. Antibodies from I to III and IV to VI are highlighted in cyan and gray blue background, respectively. Pie charts represent the frequency distribution of antibodies belonging to I to III and IV to VI. Antibodies isolated from 3-dose vaccinees are outlined by black lines.

(B) Dissociation constants (K_D) of the antibodies from I to VI. Individual class antibodies are represented in colors corresponding to the classes they belong to. The color scheme is same as Fig. 4A. BLI traces are shown in fig. S9.

(C) The measured K_D -SHM plots (left) and K_D -SHM log-log plots (right) of antibodies from I and II are shown. *IGHV3-53* and *IGHV3-66* antibodies belonging to class I and II are colored in yellow and green, respectively. The straight curves and lines are the least squares fits of the data to the power law with the values of the slope for *IGHV3-53* and *IGHV3-66* antibodies. The black curves and lines indicate the fitting of antibodies from I or II; the yellow and green ones suggest the fitting of *IGHV3-53* and *IGHV3-66* antibodies, respectively. The cyan lines are the 90% predicted interval.

References and Notes:

- 672 1. N. G. Davies, S. Abbott *et al.*, Estimated transmissibility and impact of SARS-CoV-2 lineage
673 B.1.1.7 in England. *Science* **372**, (2021); published online EpubApr 9
674 (10.1126/science.abg3055).
- 675 2. Z. Wang, F. Schmidt *et al.*, mRNA vaccine-elicited antibodies to SARS-CoV-2 and
676 circulating variants. *nature*, 616–622 (2021)10.1038/s41586-021-03324-6).
- 677 3. A. Muik, A. K. Wallisch *et al.*, Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus
678 by BNT162b2 vaccine-elicited human sera. *Science* **371**, 1152–1153 (2021); published
679 online EpubMar 12 (10.1126/science.abg6105).
- 680 4. W. F. Garcia-Beltran, E. C. Lam *et al.*, Multiple SARS-CoV-2 variants escape neutralization
681 by vaccine-induced humoral immunity. *Cell* **184**, 2372–2383 e2379 (2021); published
682 online EpubApr 29 (10.1016/j.cell.2021.03.013).
- 683 5. E. Hacisuleyman, C. Hale *et al.*, Vaccine Breakthrough Infections with SARS-CoV-2
684 Variants. *N Engl J Med* **384**, 2212–2218 (2021); published online EpubJun 10
685 (10.1056/NEJMoa2105000).
- 686 6. E. C. Sabino, L. F. Buss *et al.*, Resurgence of COVID-19 in Manaus, Brazil, despite high
687 seroprevalence. *Lancet* **397**, 452–455 (2021); published online EpubFeb 6
688 (10.1016/S0140-6736(21)00183-5).
- 689 7. W. N. Chia, F. Zhu *et al.*, Dynamics of SARS-CoV-2 neutralising antibody responses and
690 duration of immunity: a longitudinal study. *The Lancet. Microbe* **2**, e240–e249 (2021);
691 published online EpubJun (10.1016/S2666-5247(21)00025-2).
- 692 8. A. T. Widge, N. G. Rouphael *et al.*, Durability of Responses after SARS-CoV-2 mRNA-1273
693 Vaccination. *N Engl J Med* **384**, 80–82 (2021); published online EpubJan 7
694 (10.1056/NEJMc2032195).
- 695 9. Y. Zhang, G. Zeng *et al.*, Safety, tolerability, and immunogenicity of an inactivated SARS-
696 CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-
697 controlled, phase 1/2 clinical trial. *Lancet Infect Dis* **21**, 181–192 (2021); published online
698 EpubFeb (10.1016/S1473-3099(20)30843-4).
- 699 10. Q. Gao, L. Bao *et al.*, Development of an inactivated vaccine candidate for SARS-CoV-2.
700 *Science* **369**, 77–81 (2020); published online EpubJul 3 (10.1126/science.abc1932).
- 701 11. D. S. Khoury, A. K. Wheatley *et al.*, Measuring immunity to SARS-CoV-2 infection:
702 comparing assays and animal models. *Nature reviews. Immunology* **20**, 727–738 (2020);
703 published online EpubDec (10.1038/s41577-020-00471-1).
- 704 12. L. Riepler, A. Rossler *et al.*, Comparison of Four SARS-CoV-2 Neutralization Assays.
705 *Vaccines* **9**, (2020); published online EpubDec 28 (10.3390/vaccines9010013).
- 706 13. Q. W. Hongxing Pan, G. Zeng, Immunogenicity and safety of a third dose, and immune
707 persistence of CoronaVac vaccine in healthy adults aged 18–59 years: interim results from
708 a double-blind, randomized, placebo-controlled phase 2 clinical trial. *medRxiv*,
709 (2021)<https://doi.org/10.1101/2021.07.23.21261026>).
- 710 14. Z. Wang, F. Muecksch *et al.*, Naturally enhanced neutralizing breadth against SARS-CoV-
711 2 one year after infection. *Nature* **595**, 426–431 (2021); published online EpubJul
712 (10.1038/s41586-021-03696-9).
- 713 15. F. Muecksch, Y. Weisblum *et al.*, Development of potency, breadth and resilience to viral
714 escape mutations in SARS-CoV-2 neutralizing antibodies. *bioRxiv*, (2021); published
715 online EpubMar 8 (10.1101/2021.03.07.434227).
- 716 16. C. Gaebler, Z. Wang *et al.*, Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**,
717 639–644 (2021); published online EpubMar (10.1038/s41586-021-03207-w).
- 718 17. Y. Zhou, Z. Liu *et al.*, Enhancement versus neutralization by SARS-CoV-2 antibodies from
719 a convalescent donor associates with distinct epitopes on the RBD. *Cell Rep* **34**, 108699
720 (2021); published online EpubFeb 2 (10.1016/j.celrep.2021.108699).
- 721 18. D. F. Robbiani, C. Gaebler *et al.*, Convergent antibody responses to SARS-CoV-2 in
722 convalescent individuals. *Nature* **584**, 437–442 (2020); published online EpubAug

- (10.1038/s41586-020-2456-9).
19. A. C. Walls, Y. J. Park *et al.*, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **181**, 281-292 e286 (2020); published online EpubApr 16 (10.1016/j.cell.2020.02.058).
20. D. Wrapp, N. Wang *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260-1263 (2020); published online EpubMar 13 (10.1126/science.abb2507).
21. R. Yan, R. Wang *et al.*, Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. *Cell Res* **31**, 517-525 (2021); published online EpubMay (10.1038/s41422-021-00487-9).
22. W. Dejnirattisai, D. Zhou *et al.*, The antigenic anatomy of SARS-CoV-2 receptor binding domain. *Cell* **184**, 2183-2200 e2122 (2021); published online EpubApr 15 (10.1016/j.cell.2021.02.032).
23. M. Yuan, H. Liu *et al.*, Structural basis of a shared antibody response to SARS-CoV-2. *Science* **369**, 1119-1123 (2020); published online EpubAug 28 (10.1126/science.abd2321).
24. F. Bertoglio, V. Fuhner *et al.*, A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. *Cell Rep* **36**, 109433 (2021); published online EpubJul 27 (10.1016/j.celrep.2021.109433).
25. S. A. Clark, L. E. Clark *et al.*, Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2. *bioRxiv*, (2020); published online EpubNov 13 (10.1101/2020.11.13.381533).
26. B. B. Banach, G. Cerutti *et al.*, Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. *bioRxiv*, (2021); published online EpubJan 3 (10.1101/2020.12.31.424987).
27. B. E. Jones, P. L. Brown-Augsburger *et al.*, The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. *Sci Transl Med* **13**, (2021); published online EpubMay 12 (10.1126/scitranslmed.abf1906).
28. Y. Guo, L. Huang *et al.*, A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. *Nat Commun* **12**, 2623 (2021); published online EpubMay 11 (10.1038/s41467-021-22926-2).
29. S. Du, Y. L. Cao *et al.*, Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. *Cell* **183**, 1013-+ (2020); published online EpubNov 12 (10.1016/j.cell.2020.09.035).
30. W. Dejnirattisai, D. M. Zhou *et al.*, Antibody evasion by the P.1 strain of SARS-CoV-2. *Cell* **184**, 2939-+ (2021); published online EpubMay 27 (10.1016/j.cell.2021.03.055).
31. C. O. Barnes, C. A. Jette *et al.*, SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature* **588**, 682-+ (2020); published online EpubDec 24 (10.1038/s41586-020-2852-1).
32. N. C. Wu, M. Yuan *et al.*, An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. *Cell Reports* **33**, (2020); published online EpubOct 20 (10.1016/J.Celrep.2020.108274).
33. H. J. Liu, N. C. Wu *et al.*, Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. *Immunity* **53**, 1272-+ (2020); published online EpubDec 15 (10.1016/j.immuni.2020.10.023).
34. N. K. Hurlburt, E. Seydoux *et al.*, Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. *Nature Communications* **11**, (2020); published online EpubOct 27 (10.1038/s41467-020-19231-9).
35. Y. Wu, F. R. Wang *et al.*, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science* **368**, 1274-+ (2020); published online EpubJun 12 (10.1126/science.abc2241).

- 774 36. R. Shi, C. Shan *et al.*, A human neutralizing antibody targets the receptor-binding site of
775 SARS-CoV-2. *Nature* **584**, 120-+ (2020); published online EpubAug 6 (10.1038/s41586-
776 020-2381-y).
- 777 37. J. W. Ge, R. K. Wang *et al.*, Antibody neutralization of SARS-CoV-2 through ACE2 receptor
778 mimicry. *Nature Communications* **12**, (2021); published online EpubJan 11
779 (10.1038/s41467-020-20501-9).
- 780 38. C. O. Barnes, A. P. West *et al.*, Structures of Human Antibodies Bound to SARS-CoV-2
781 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-+
782 (2020); published online EpubAug 20 (10.1016/j.cell.2020.06.025).
- 783 39. H. P. Yao, Y. Sun *et al.*, Rational development of a human antibody cocktail that deploys
784 multiple functions to confer Pan-SARS-CoVs protection. *Cell Research* **31**, 25-36 (2021);
785 published online EpubJan (10.1038/s41422-020-00444-y).
- 786 40. N. Wang, Y. Sun *et al.*, Structure-based development of human antibody cocktails against
787 SARS-CoV-2. *Cell Research* **31**, 101-103 (2021); published online EpubJan
788 (10.1038/s41422-020-00446-w).
- 789 41. S. Miersch, Z. Li, Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced
790 Potency and Resistance to Escape Mutations. *BioRxiv*,
791 (2021)<https://doi.org/10.1101/2020.10.31.362848>).
- 792 42. C. J. Bracken, S. A. Lim *et al.*, Bi-paratopic and multivalent VH domains block ACE2 binding
793 and neutralize SARS-CoV-2. *Nature chemical biology* **17**, 113-121 (2021); published
794 online EpubJan (10.1038/s41589-020-00679-1).
- 795 43. C. Zhang, Y. F. Wang *et al.*, Development and structural basis of a two-MAb cocktail for
796 treating SARS-CoV-2 infections. *Nature Communications* **12**, (2021); published online
797 EpubJan 11 (10.1038/s41467-020-20465-w).
- 798 44. L. Piccoli, Y. J. Park *et al.*, Mapping Neutralizing and Immunodominant Sites on the SARS-
799 CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
800 *Cell* **183**, 1024-+ (2020); published online EpubNov 12 (10.1016/j.cell.2020.09.037).
- 801 45. J. Hansen, A. Baum *et al.*, Studies in humanized mice and convalescent humans yield a
802 SARS-CoV-2 antibody cocktail. *Science* **369**, 1010-1014 (2020); published online
803 EpubAug 21 (10.1126/science.abd0827).
- 804 46. J. Kreye, S. M. Reincke *et al.*, A Therapeutic Non-self-reactive SARS-CoV-2 Antibody
805 Protects from Lung Pathology in a COVID-19 Hamster Model. *Cell* **183**, 1058-+ (2020);
806 published online EpubNov 12 (10.1016/j.cell.2020.09.049).
- 807 47. R. Rouet, O. Mazigi *et al.*, Potent SARS-CoV-2 binding and neutralization through
808 maturation of iconic SARS-CoV-1 antibodies. *Mabs-Austin* **13**, (2021); published online
809 EpubJan 1 (10.1080/19420862.2021.1922134).
- 810 48. M. A. Tortorici, M. Beltramello *et al.*, Ultrapotent human antibodies protect against SARS-
811 CoV-2 challenge via multiple mechanisms. *Science* **370**, 950-+ (2020); published online
812 EpubNov 20 (10.1126/science.abe3354).
- 813 49. E. Ruja, I. Kucharska *et al.*, Multivalency transforms SARS-CoV-2 antibodies into
814 ultrapotent neutralizers. *Nature Communications* **12**, (2021); published online EpubJun
815 16 (10.1038/s41467-021-23825-2).
- 816 50. J. Ahmad, J. Jiang *et al.*, Synthetic nanobody-SARS-CoV-2 receptor-binding domain
817 structures identify distinct epitopes. *bioRxiv*, (2021); published online EpubJan 27
818 (10.1101/2021.01.27.428466).
- 819 51. M. Schoof, B. Faust *et al.*, An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by
820 stabilizing inactive Spike. *Science* **370**, 1473-1479 (2020); published online EpubDec 18
821 (10.1126/science.abe3255).
- 822 52. M. Rapp, Y. C. Guo *et al.*, Modular basis for potent SARS-CoV-2 neutralization by a
823 prevalent VH1-2-derived antibody class. *Cell Reports* **35**, (2021); published online
824 EpubApr 6 (10.1016/j.celrep.2021.108950).

825 53. C. Kim, D. K. Ryu *et al.*, A therapeutic neutralizing antibody targeting receptor binding
826 domain of SARS-CoV-2 spike protein. *Nature Communications* **12**, (2021); published
827 online EpubJan 12 (10.1038/s41467-020-20602-5).

828 54. D. Li, R. J. Edwards *et al.*, In vitro and in vivo functions of SARS-CoV-2 infection-enhancing
829 and neutralizing antibodies. *Cell*, (2021); published online EpubJun 18
830 (10.1016/j.cell.2021.06.021).

831 55. L. Hanke, L. V. Perez *et al.*, An alpaca nanobody neutralizes SARS-CoV-2 by blocking
832 receptor interaction. *Nature Communications* **11**, (2020); published online EpubSep 4
833 (10.1038/s41467-020-18174-5).

834 56. J. D. Huo, A. Le Bas *et al.*, Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block
835 interaction with ACE2 (vol 27, pg 846, 2020). *Nature Structural & Molecular Biology* **28**,
836 326-326 (2021); published online EpubMar (10.1038/s41594-021-00566-w).

837 57. B. Ju, Q. Zhang *et al.*, Human neutralizing antibodies elicited by SARS-CoV-2 infection.
838 *Nature* **584**, 115-+ (2020); published online EpubAug 6 (10.1038/s41586-020-2380-z).

839 58. Y. L. Cao, B. Su *et al.*, Potent Neutralizing Antibodies against SARS-CoV-2 Identified by
840 High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. *Cell* **182**, 73-
841 + (2020); published online EpubJul 9 (10.1016/j.cell.2020.05.025).

842 59. L. H. Liu, P. F. Wang *et al.*, Potent neutralizing antibodies against multiple epitopes on
843 SARS-CoV-2 spike. *Nature* **584**, 450-+ (2020); published online EpubAug 20
844 (10.1038/s41586-020-2571-7).

845 60. P. A. Koenig, H. Das *et al.*, Structure-guided multivalent nanobodies block SARS-CoV-2
846 infection and suppress mutational escape. *Science* **371**, 691-+ (2021); published online
847 EpubFeb 12 (10.1126/science.abe6230).

848 61. Y. F. Xiang, S. Nambulli *et al.*, Versatile and multivalent nanobodies efficiently neutralize
849 SARS-CoV-2. *Science* **370**, 1479-1484 (2020); published online EpubDec 18
850 (10.1126/science.abe4747).

851 62. L. Zhu, Y. Q. Deng *et al.*, Double lock of a potent human therapeutic monoclonal antibody
852 against SARS-CoV-2. *National Science Review* **8**, (2021); published online EpubMar
853 (10.1093/nsr/nwaa297).

854 63. G. Cerutti, M. Rapp *et al.*, Structural basis for accommodation of emerging B.1.351 and
855 B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. *Structure* **29**, 655-+
856 (2021); published online EpubJul 1 (10.1016/j.str.2021.05.014).

857 64. T. F. Custodio, H. Das *et al.*, Selection, biophysical and structural analysis of synthetic
858 nanobodies that effectively neutralize SARS-CoV-2. *Nature Communications* **11**, (2020);
859 published online EpubNov 4 (10.1038/s41467-020-19204-Y).

860 65. J. F. Scheid, C. O. Barnes *et al.*, B cell genomics behind cross-neutralization of SARS-CoV-
861 2 variants and SARS-CoV. *Cell* **184**, 3205-+ (2021); published online EpubJun 10
862 (10.1016/j.cell.2021.04.032).

863 66. H. J. Liu, M. Yuan *et al.*, A combination of cross-neutralizing antibodies synergizes to
864 prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. *Cell Host & Microbe* **29**, 806-
865 + (2021); published online EpubMay 12 (10.1016/j.chom.2021.04.005).

866 67. D. Pinto, Y. J. Park *et al.*, Cross-neutralization of SARS-CoV-2 by a human monoclonal
867 SARS-CoV antibody. *Nature* **583**, 290-295 (2020); published online EpubJul
868 (10.1038/s41586-020-2349-y).

869 68. T. N. Starr, N. Czudnochowski *et al.*, Antibodies to the SARS-CoV-2 receptor-binding
870 domain that maximize breadth and resistance to viral escape. *bioRxiv*, (2021).

871 69. D. M. Zhou, H. M. E. Duyvesteyn *et al.*, Structural basis for the neutralization of SARS-
872 CoV-2 by an antibody from a convalescent patient. *Nature Structural & Molecular Biology*
873 **27**, 950-+ (2020); published online EpubOct (10.1038/s41594-020-0480-y).

874 70. M. Yuan, N. C. Wu *et al.*, A highly conserved cryptic epitope in the receptor binding
875 domains of SARS-CoV-2 and SARS-CoV. *Science* **368**, 630-+ (2020); published online

876 EpubMay 8 (10.1126/science.abb7269).

877 71. Z. Lv, Y. Q. Deng *et al.*, Structural basis for neutralization of SARS-CoV-2 and SARS-CoV
878 by a potent therapeutic antibody. *Science* **369**, 1505-+ (2020); published online EpubSep
879 18 (10.1126/science.abc5881).

880 72. Y. L. Cao, A. Yisimayi *et al.*, Humoral immune response to circulating SARS-CoV-2 variants
881 elicited by inactivated and RBD-subunit vaccines. *Cell Research* **31**, 732-741 (2021);
882 published online EpubJul (10.1038/s41422-021-00514-9).

883 73. Y. Sun, L. Wang *et al.*, Structure-based development of three- and four-antibody cocktails
884 against SARS-CoV-2 via multiple mechanisms. *Cell Research* **31**, 597-600 (2021);
885 published online EpubMay (10.1038/s41422-021-00497-7).

886 74. X. Zhu, D. Mannar *et al.*, Cryo-electron microscopy structures of the N501Y SARS-CoV-2
887 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. *PLoS Biol* **19**,
888 e3001237 (2021); published online EpubApr (10.1371/journal.pbio.3001237).

889 75. D. Asarnow, B. Wang *et al.*, Structural insight into SARS-CoV-2 neutralizing antibodies
890 and modulation of syncytia. *Cell* **184**, 3192-+ (2021); published online EpubJun 10
891 (10.1016/j.cell.2021.04.033).

892 76. X. J. Zhou, F. G. Ma *et al.*, Diverse immunoglobulin gene usage and convergent epitope
893 targeting in neutralizing antibody responses to SARS-CoV-2. *Cell Reports* **35**, (2021);
894 published online EpubMay 11 (10.1016/j.celrep.2021.109109).

895 77. M. F. Jennewein, A. J. MacCamy *et al.*, Isolation and characterization of cross-neutralizing
896 coronavirus antibodies from COVID-19+ subjects. *Cell Rep* **36**, 109353 (2021); published
897 online EpubJul 13 (10.1016/j.celrep.2021.109353).

898 78. T. N. Starr, N. Czudnochowski *et al.*, SARS-CoV-2 RBD antibodies that maximize breadth
899 and resistance to escape. *Nature*, 1-9 (2021).

900 79. J. Fedry, D. L. Hurdiss *et al.*, Structural insights into the cross-neutralization of SARS-CoV
901 and SARS-CoV-2 by the human monoclonal antibody 47D11. *Science Advances* **7**,
902 (2021); published online EpubJun (10.1126/sciadv.abf5632).

903 80. K. Westendorf, S. Zentelis *et al.*, LY-CoV1404 potently neutralizes SARS-CoV-2 variants.
904 *bioRxiv*, (2021); published online EpubMay 4 (10.1101/2021.04.30.442182).

905 81. C. Liu, H. M. Ginn *et al.*, Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and
906 convalescent serum. *Cell*, (2021); published online EpubJun 17
907 (10.1016/j.cell.2021.06.020).

908 82. L. Wang, T. Zhou *et al.*, Ultrapotent antibodies against diverse and highly transmissible
909 SARS-CoV-2 variants. *Science*, (2021); published online EpubJul 1
910 (10.1126/science.abh1766).

911 83. L. Zhang, L. Cao *et al.*, A proof of concept for neutralizing antibody-guided vaccine design
912 against SARS-CoV-2. *National Science Review*, (2020)10.1093/nsr/nwab053).

913 84. J. Huo, Y. Zhao *et al.*, Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
914 *Cell Host Microbe* **28**, 445-454 e446 (2020); published online EpubSep 9
915 (10.1016/j.chom.2020.06.010).

916 85. M. McCallum, A. De Marco *et al.*, N-terminal domain antigenic mapping reveals a site of
917 vulnerability for SARS-CoV-2. *Cell* **184**, 2332-2347 e2316 (2021); published online
918 EpubApr 29 (10.1016/j.cell.2021.03.028).

919 86. G. Cerutti, Y. Guo *et al.*, Potent SARS-CoV-2 neutralizing antibodies directed against spike
920 N-terminal domain target a single supersite. *Cell Host Microbe* **29**, 819-833 e817 (2021);
921 published online EpubMay 12 (10.1016/j.chom.2021.03.005).

922 87. X. Y. Chi, R. H. Yan *et al.*, A neutralizing human antibody binds to the N-terminal domain
923 of the Spike protein of SARS-CoV-2. *Science* **369**, 650-+ (2020); published online
924 EpubAug 7 (10.1126/science.abc6952).

925 88. W. N. Voss, Y. X. J. Hou *et al.*, Prevalent, protective, and convergent IgG recognition of
926 SARS-CoV-2 non-RBD spike epitopes. *Science* **372**, 1108-+ (2021); published online

- 927 EpubJun 4 (10.1126/science.abg5268).
- 928 89. A. Rosa, V. E. Pye *et al.*, SARS-CoV-2 can recruit a heme metabolite to evade antibody
929 immunity. *Science Advances* **7**, (2021); published online EpubMay
930 (10.1126/sciadv.abg7607).
- 931 90. Y. F. Liu, W. T. Soh *et al.*, An infectivity-enhancing site on the SARS-CoV-2 spike protein
932 targeted by antibodies. *Cell* **184**, 3452-+ (2021); published online EpubJun 24
933 (10.1016/j.cell.2021.05.032).
- 934 91. P. J. M. Brouwer, T. G. Caniels *et al.*, Potent neutralizing antibodies from COVID-19
935 patients define multiple targets of vulnerability. *Science* **369**, 643-+ (2020); published
936 online EpubAug 7 (10.1126/science.abc5902).
- 937 92. T. Noy-Porat, A. Mechaly *et al.*, Therapeutic antibodies, targeting the SARS-CoV-2 spike
938 N-terminal domain, protect lethally infected K18-hACE2 mice. *Isience* **24**, (2021);
939 published online EpubMay 21 (10.1016/j.isci.2021.102479).
- 940 93. J. Goike, C. L. Hsieh *et al.*, Synthetic repertoires derived from convalescent COVID-19
941 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary
942 binding modality. *bioRxiv*, (2021); published online EpubApr 9
943 (10.1101/2021.04.07.438849).
- 944 94. P. Wang, M. S. Nair *et al.*, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
945 *Nature* **593**, 130-135 (2021); published online EpubMay (10.1038/s41586-021-03398-2).
- 946 95. J. Lopez Bernal, N. Andrews *et al.*, Effectiveness of Covid-19 Vaccines against the B.1.617.2
947 (Delta) Variant. *N Engl J Med*, (2021); published online EpubJul 21
948 (10.1056/NEJMoa2108891).
- 949 96. A. Sheikh, J. McMenamin *et al.*, SARS-CoV-2 Delta VOC in Scotland: demographics, risk
950 of hospital admission, and vaccine effectiveness. *Lancet* **397**, 2461-2462 (2021); published
951 online EpubJun 26 (10.1016/S0140-6736(21)01358-1).
- 952 97. R. Wang, Q. Zhang *et al.*, Analysis of SARS-CoV-2 variant mutations reveals neutralization
953 escape mechanisms and the ability to use ACE2 receptors from additional species.
954 *Immunity* **54**, 1611-1621 e1615 (2021); published online EpubJul 13
955 (10.1016/j.immuni.2021.06.003).
- 956 98. P. L. Shuo Du, Zhiying Zhang, Structures of SARS-CoV-2 B.1.351 neutralizing antibodies
957 provide insights into cocktail design against concerning variants. *bioRxiv*,
958 (2021)<https://doi.org/10.1101/2021.07.30.454402>.
- 959 99. M. Yuan, D. Huang *et al.*, Structural and functional ramifications of antigenic drift in recent
960 SARS-CoV-2 variants. *Science*, (2021); published online EpubMay 20
961 (10.1126/science.abh1139).
- 962 100. R. T. E. Chen, X. W. Zhang *et al.*, Resistance of SARS-CoV-2 variants to neutralization by
963 monoclonal and serum-derived polyclonal antibodies. *Nature Medicine* **27**, (2021);
964 published online EpubApr (10.1038/s41591-021-01294-w).
- 965 101. D. K. Ryu, R. Song *et al.*, Therapeutic effect of CT-P59 against SARS-CoV-2 South African
966 variant. *Biochem Biophys Res Commun* **566**, 135-140 (2021); published online EpubAug
967 20 (10.1016/j.bbrc.2021.06.016).
- 968 102. P. Wang, R. G. Casner *et al.*, Increased resistance of SARS-CoV-2 variant P.1 to antibody
969 neutralization. *Cell Host Microbe* **29**, 747-751 e744 (2021); published online EpubMay 12
970 (10.1016/j.chom.2021.04.007).
- 971 103. D. Zhou, W. Dejnirattisai *et al.*, Evidence of escape of SARS-CoV-2 variant B.1.351 from
972 natural and vaccine-induced sera. *Cell* **184**, 2348-2361 e2346 (2021); published online
973 EpubApr 29 (10.1016/j.cell.2021.02.037).
- 974 104. P. Supasa, D. Zhou *et al.*, Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by
975 convalescent and vaccine sera. *Cell* **184**, 2201-2211 e2207 (2021); published online
976 EpubApr 15 (10.1016/j.cell.2021.02.033).
- 977 105. X. Y. Shen, H. L. Tang *et al.*, SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing

978 antibodies elicited by ancestral spike vaccines. *Cell Host & Microbe* **29**, 529-+ (2021);
979 published online EpubApr 14 (10.1016/j.chom.2021.03.002).
980 106. D. R. Martinez, A. Schaefer *et al.*, A broadly neutralizing antibody protects against SARS-
981 CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice. *bioRxiv*, (2021);
982 published online EpubApr 28 (10.1101/2021.04.27.441655).
983 107. D. A. Collier, A. De Marco *et al.*, Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-
984 elicited antibodies. *Nature* **593**, 136-141 (2021); published online EpubMay
985 (10.1038/s41586-021-03412-7).
986 108. R. E. Chen, E. S. Winkler *et al.*, In vivo monoclonal antibody efficacy against SARS-CoV-2
987 variant strains. *Nature*, (2021); published online EpubJun 21 (10.1038/s41586-021-
988 03720-y).

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013